Keros Therapeutics, Inc. (NASDAQ:KROS) Given Consensus Rating of "Moderate Buy" by Analysts

Shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the fourteen brokerages that are presently covering the stock, Marketbeat Ratings reports. Seven analysts have rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $30.56.

Several research analysts recently weighed in on KROS shares. Wedbush reissued a "neutral" rating and issued a $15.00 target price on shares of Keros Therapeutics in a research note on Friday, May 30th. HC Wainwright reduced their target price on Keros Therapeutics from $40.00 to $25.00 and set a "buy" rating on the stock in a report on Thursday, May 8th. Truist Financial decreased their price objective on shares of Keros Therapeutics from $43.00 to $25.00 and set a "buy" rating for the company in a research note on Wednesday, April 9th. Scotiabank decreased their target price on Keros Therapeutics from $41.00 to $26.00 and set a "sector outperform" rating for the company in a research report on Monday, May 12th. Finally, Wells Fargo & Company lowered their price target on shares of Keros Therapeutics from $28.00 to $26.00 and set an "overweight" rating for the company in a report on Thursday, February 27th.

Insider Activity at Keros Therapeutics

In related news, major shareholder Adar1 Capital Management, Llc purchased 934,258 shares of the business's stock in a transaction that occurred on Wednesday, April 9th. The shares were acquired at an average price of $10.13 per share, with a total value of $9,464,033.54. Following the acquisition, the insider now owns 4,392,737 shares in the company, valued at approximately $44,498,425.81. This trade represents a 27.01% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 20.60% of the company's stock.

Institutional Trading of Keros Therapeutics

A number of large investors have recently modified their holdings of the company. JPMorgan Chase & Co. raised its stake in shares of Keros Therapeutics by 585.9% during the fourth quarter. JPMorgan Chase & Co. now owns 213,431 shares of the company's stock valued at $3,379,000 after purchasing an additional 182,314 shares in the last quarter. Darwin Global Management Ltd. boosted its position in shares of Keros Therapeutics by 10.7% in the 4th quarter. Darwin Global Management Ltd. now owns 1,687,135 shares of the company's stock valued at $26,707,000 after purchasing an additional 163,403 shares during the period. Norges Bank acquired a new position in shares of Keros Therapeutics in the fourth quarter worth about $1,027,000. BNP Paribas Financial Markets acquired a new position in Keros Therapeutics in the 4th quarter worth approximately $730,000. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Keros Therapeutics in the fourth quarter worth $461,000. Institutional investors and hedge funds own 71.56% of the company's stock.

Keros Therapeutics Trading Up 0.3%

Shares of NASDAQ:KROS traded up $0.04 on Wednesday, reaching $13.79. 428,821 shares of the company were exchanged, compared to its average volume of 861,272. The company has a 50-day moving average of $13.59 and a 200-day moving average of $17.44. Keros Therapeutics has a 1-year low of $9.12 and a 1-year high of $72.37. The firm has a market cap of $560.08 million, a price-to-earnings ratio of -2.65 and a beta of 1.31.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last announced its earnings results on Tuesday, May 6th. The company reported $3.62 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.01) by $3.63. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The company had revenue of $211.25 million during the quarter, compared to analysts' expectations of $84.62 million. During the same quarter in the previous year, the business posted ($1.21) earnings per share. As a group, analysts forecast that Keros Therapeutics will post -4.74 earnings per share for the current year.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.